Krystal Biotech, Inc. (KRYS) financial statements (2021 and earlier)

Company profile

Business Address 2100 WHARTON STREET
PITTSBURGH, PA 15203
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:271286297187194203196
Cash and cash equivalents268282292180188195187
Short-term investments34566  
Other undisclosed cash, cash equivalents, and short-term investments000(0)089
Prepaid expense 2     
Other undisclosed current assets4(1)12211
Total current assets:275288299188196204196
Noncurrent Assets
Operating lease, right-of-use asset323333 
Property, plant and equipment31181310876
Long-term investments and receivables    0  
Long-term investments    0  
Other noncurrent assets2112100
Other undisclosed noncurrent assets 222  3
Total noncurrent assets:3624201713109
TOTAL ASSETS:311311318205209214205
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3321111
Accounts payable2321111
Accrued liabilities1000000
Debt  1100 
Other liabilities0000000
Other undisclosed current liabilities13433223
Total current liabilities:15764344
Noncurrent Liabilities
Long-term debt and lease obligation333333 
Operating lease, liability333333 
Other undisclosed noncurrent liabilities(3)(3)    3
Total noncurrent liabilities: 333333
Total liabilities:191087677
Stockholders' equity
Stockholders' equity attributable to parent292302310198203208198
Additional paid in capital363363361243242241228
Accumulated other comprehensive income0000000
Accumulated deficit(71)(61)(51)(44)(39)(34)(29)
Total stockholders' equity:292302310198203208198
TOTAL LIABILITIES AND EQUITY:311311318205209214205

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(10)(10)(7)(6)(6)(5)(6)
Operating loss:(10)(10)(7)(6)(6)(5)(6)
Nonoperating income      1
Net loss:(10)(10)(7)(6)(6)(5)(5)
Other undisclosed net income attributable to parent000111 
Net loss available to common stockholders, diluted:(10)(10)(7)(5)(5)(4)(5)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(10)(10)(7)(6)(6)(5)(5)
Comprehensive loss:(10)(10)(7)(6)(6)(5)(5)
Other undisclosed comprehensive income, net of tax, attributable to parent0001110
Comprehensive loss, net of tax, attributable to parent:(10)(10)(7)(5)(5)(4)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: